Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13409520 | 0.81 | GSK3B (0.39) | GSK3BCES2CES1DAO | |
| SCHEMBL660893 | 0.79 | POLB (0.46) | GSK3BDAO | |
| SCHEMBL1359642 | 0.78 | GSK3B (0.67) | GSK3BPTPN1 | |
| SCHEMBL193501 | 0.77 | GSK3B (1.00) | GSK3BCES2CES1DAO | |
| SCHEMBL18153171 | 0.77 | GSK3B (0.64) | GSK3BPTPN1DAO | |
| SCHEMBL4806223 | 0.75 | GSK3B (0.62) | GSK3BPTPN1CES2CES1DAO | |
| SCHEMBL11172498 | 0.75 | GSK3B (0.62) | GSK3BPTPN1CES2CES1DAO | |
| SCHEMBL230769 | 0.75 | GSK3B (0.68) | GSK3BDAO | |
| SCHEMBL6394534 | 0.75 | GSK3B (0.62) | GSK3BDAO | |
| SCHEMBL2974396 | 0.75 | MELK (0.37) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050051-B | Purification method of 2-bromo-1- (5-iodothiophene-2-yl) -ethanone | Shanghai yaotan pharmaceutical research and Development Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-117050051-A | Purification method of 2-bromo-1- (5-iodothiophene-2-yl) -ethanone | 上海药坦药物研究开发有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-117050051-B | Purification method of 2-bromo-1- (5-iodothiophene-2-yl) -ethanone | Shanghai yaotan pharmaceutical research and Development Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117050051-B | Purification method of 2-bromo-1- (5-iodothiophene-2-yl) -ethanone | Shanghai yaotan pharmaceutical research and Development Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117050051-B | Purification method of 2-bromo-1- (5-iodothiophene-2-yl) -ethanone | Shanghai yaotan pharmaceutical research and Development Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117050051-A | Purification method of 2-bromo-1- (5-iodothiophene-2-yl) -ethanone | 上海药坦药物研究开发有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-117050051-A | Purification method of 2-bromo-1- (5-iodothiophene-2-yl) -ethanone | 上海药坦药物研究开发有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-117050051-A | Purification method of 2-bromo-1- (5-iodothiophene-2-yl) -ethanone | 上海药坦药物研究开发有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-3057963-B1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-3057963-A1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | Boehringer Ingelheim International GmbH (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| WO-2015055698-A1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | SLC6A7, SLC7A11, SLC7A1 | GSK3B 3668/4885PTPN1 3507/4885CES2 1015/4885 |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | GSK3B 241/4885PTPN1 1702/4885CES2 4293/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | GSK3B 241/4885PTPN1 1702/4885CES2 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.